JP2005506035A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506035A5
JP2005506035A5 JP2002545640A JP2002545640A JP2005506035A5 JP 2005506035 A5 JP2005506035 A5 JP 2005506035A5 JP 2002545640 A JP2002545640 A JP 2002545640A JP 2002545640 A JP2002545640 A JP 2002545640A JP 2005506035 A5 JP2005506035 A5 JP 2005506035A5
Authority
JP
Japan
Prior art keywords
seq
protein
hodgkin
antibody
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002545640A
Other languages
English (en)
Japanese (ja)
Other versions
JP4303964B2 (ja
JP2005506035A (ja
Filing date
Publication date
Priority claimed from US09/724,406 external-priority patent/US7090843B1/en
Application filed filed Critical
Publication of JP2005506035A publication Critical patent/JP2005506035A/ja
Publication of JP2005506035A5 publication Critical patent/JP2005506035A5/ja
Application granted granted Critical
Publication of JP4303964B2 publication Critical patent/JP4303964B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002545640A 2000-11-28 2001-11-28 組換え抗cd30抗体およびその使用 Expired - Lifetime JP4303964B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/724,406 US7090843B1 (en) 2000-11-28 2000-11-28 Recombinant anti-CD30 antibodies and uses thereof
PCT/US2001/044811 WO2002043661A2 (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2005506035A JP2005506035A (ja) 2005-03-03
JP2005506035A5 true JP2005506035A5 (enExample) 2005-12-22
JP4303964B2 JP4303964B2 (ja) 2009-07-29

Family

ID=24910311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002545640A Expired - Lifetime JP4303964B2 (ja) 2000-11-28 2001-11-28 組換え抗cd30抗体およびその使用

Country Status (12)

Country Link
US (1) US7090843B1 (enExample)
EP (1) EP1347730B2 (enExample)
JP (1) JP4303964B2 (enExample)
AT (1) ATE454124T1 (enExample)
AU (2) AU3651802A (enExample)
CA (1) CA2430135C (enExample)
CY (1) CY1110700T1 (enExample)
DE (1) DE60141043D1 (enExample)
DK (1) DK1347730T4 (enExample)
ES (1) ES2339333T5 (enExample)
PT (1) PT1347730E (enExample)
WO (1) WO2002043661A2 (enExample)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
EP1482972A4 (en) * 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
WO2003055527A2 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
CA2471702C (en) * 2002-01-09 2013-03-19 Medarex, Inc. Human monoclonal antibodies against cd30
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
ES2544527T3 (es) * 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP1802345A2 (en) 2004-10-01 2007-07-04 Medarex, Inc. Methods of treating cd30 positive lymphomas
NZ560209A (en) 2005-02-18 2009-04-30 Medarex Inc Monoclonal antibodies against CD30 lacking in fucosyl residues
EP1951757B1 (en) 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
MX2010003977A (es) * 2007-10-12 2010-04-30 Seattle Genetics Inc Terapia de combinacion con conjugados de anticuerpo-farmaco.
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
WO2010027513A2 (en) 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
CA3159253A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR101224468B1 (ko) * 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CN103561759B (zh) 2010-10-22 2016-10-12 西雅图遗传学公司 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
CN110078818B (zh) * 2012-04-27 2023-12-29 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AU2013364065B2 (en) 2012-12-21 2018-10-04 Altrubio Inc. Hydrophilic self-immolative linkers and conjugates thereof
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US20140286969A1 (en) 2013-03-15 2014-09-25 Abbvie Inc. Anti-egfr antibody drug conjugate formulations
AU2014240012A1 (en) 2013-03-15 2015-09-24 Abbvie Inc. Antibody drug conjugate (ADC) purification
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
KR102645430B1 (ko) 2013-10-15 2024-03-11 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
JP2017510548A (ja) 2014-01-29 2017-04-13 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
RU2017101662A (ru) 2014-06-20 2018-07-23 Биоэллаенс К.В. Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения
EP3682904A1 (en) 2014-06-30 2020-07-22 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
AU2015242210A1 (en) 2015-06-15 2017-12-07 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers for conjugation
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
SI3380620T1 (sl) 2015-11-23 2024-09-30 Novartis Ag Optimizirani lentivirusni prenosni vektorji in njihove uporabe
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
RU2766000C2 (ru) 2016-01-08 2022-02-07 АльтруБио Инк. Четырехвалентные антитела к psgl-1 и их применения
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
JP7523907B2 (ja) 2016-11-14 2024-07-29 武田薬品工業株式会社 非成人のヒトに対する抗cd30抗体-薬物コンジュゲートの投与
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN111526893A (zh) 2017-10-11 2020-08-11 西雅图知耐特公司 减少抗cd30抗体药物偶联物疗法的副作用的方法
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MX2020004229A (es) 2017-10-25 2020-07-22 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
US20220226439A1 (en) 2017-11-01 2022-07-21 Seagen Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
WO2019183438A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3856777A1 (en) 2018-09-24 2021-08-04 The Medical College of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
KR20210066833A (ko) 2018-09-26 2021-06-07 지앙수 헨그루이 메디슨 컴퍼니 리미티드 엑사테칸 유사체의 리간드-약물 접합체, 이를 위한 제조 방법, 및 이의 적용
MX2021003734A (es) 2018-10-01 2021-07-16 Seagen Inc Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
WO2020210719A1 (en) 2019-04-10 2020-10-15 Elevatebio Management, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
JP7467610B2 (ja) 2019-09-18 2024-04-15 バイリ-バイオ(チェンドゥ)ファーマスーティカル シーオー.,エルティーディー. カンプトテシン誘導体及びその複合体
EP4034154A1 (en) 2019-09-25 2022-08-03 Seagen Inc. Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CA3160151A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
CA3168654A1 (en) 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
EP4096713A1 (en) 2020-01-31 2022-12-07 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
JP7730836B2 (ja) 2020-03-25 2025-08-28 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体の調製方法
JP7689979B2 (ja) 2020-03-25 2025-06-09 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体を含む医薬組成物及びその使用
IL297167A (en) 2020-04-10 2022-12-01 Seagen Inc Charging variant connectors
WO2021231568A1 (en) 2020-05-13 2021-11-18 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20230133331A (ko) 2021-01-15 2023-09-19 씨젠 인크. 면역조절 항체-약물 컨쥬게이트
EP4308170A1 (en) 2021-03-18 2024-01-24 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
IL307548A (en) 2021-04-20 2023-12-01 Seagen Inc Modulation of antibody-dependent cellular cytotoxicity
JP2024515793A (ja) 2021-04-27 2024-04-10 ノバルティス アーゲー ウイルスベクター生産システム
JP2024520562A (ja) 2021-05-28 2024-05-24 シージェン インコーポレイテッド アントラサイクリン抗体コンジュゲート
CA3236735A1 (en) 2021-10-29 2023-05-04 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
AU2023365454A1 (en) 2022-10-18 2025-04-03 Meiji Seika Pharma Co., Ltd. Therapeutic agent for t cell malignancies
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
TW202500193A (zh) 2023-03-22 2025-01-01 美商信立泰生物醫藥公司 抗5t4抗原結合結構域、抗體-藥物共軛體及彼等之使用方法
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2025090774A1 (en) 2023-10-24 2025-05-01 Seagen Inc. Chemotherapeutic compounds and methods of use
WO2025096626A1 (en) 2023-10-31 2025-05-08 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025169056A1 (en) 2024-02-06 2025-08-14 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
CN119331093B (zh) * 2024-11-04 2025-07-11 武汉伊莱瑞特生物科技股份有限公司 一种抗CD30的兔源Fab抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1991007437A2 (en) 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
EP0671923B1 (en) 1992-10-09 2001-04-18 Advanced Tissue Sciences, Inc. Liver reserve cells
EP0678523B1 (en) 1993-01-14 2004-09-15 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-hiv antibody and preparation thereof
EP0771208B1 (en) * 1994-08-12 2005-10-19 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6033876A (en) 1995-01-18 2000-03-07 Boehringer Mannheim Gmbh Anti-CD30 antibodies preventing proteolytic cleavage and release of membrane-bound CD30 antigen
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
DE19640733A1 (de) * 1996-10-02 1998-04-09 Abken Hinrich Verfahren zur Hemmung der unbegrenzten Profileration, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen
ATE372130T1 (de) 2000-04-22 2007-09-15 Pharmedartis Gmbh Apoptotika
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
EP1482972A4 (en) 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES

Similar Documents

Publication Publication Date Title
JP2005506035A5 (enExample)
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
CA2430135A1 (en) Recombinant anti-cd30 antibodies and uses thereof
US5639455A (en) Immunosuppressant
ES2346184T3 (es) Antagonistas de cd30 o cd30l para usar en el tratamiento de enfermedades antiinflamatorias cronicas y autoinmunes.
CN1322897C (zh) Il-18抑制剂的应用
CA2253239C (en) Antibodies against interferon alpha/beta receptor
AU2001281163A1 (en) Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
KR970701776A (ko) 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1)
EP0948353A1 (en) Methods and compositions for immunomodulation
JP4495776B1 (ja) 融合蛋白質
US11505619B2 (en) Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
CA2375827C (en) A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US20210238295A1 (en) Compositions and methods for treating abdominal aortic aneurysm
CN101626785A (zh) 神经延长促进剂及延长抑制剂
JPH07508763A (ja) ヒトγインターフェロンのアンタゴニスト
CN111072780B (zh) 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用
MXPA99003283A (en) Methods and compositions for immunomodulation